News

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.
Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia ...
With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...
Eli Lilly and Company (NYSE: LLY) is one of the best long term low volatility stocks to buy now. In a report released on July ...
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...
Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Alzheimer’s Association’s Bike to End ALZ cycling fundraiser across SC from Simpsonville to Charleston finished in Mount ...
Saturday at the Dream Center, the Bismarck Memory Cafe hosted a presentation from the Alzheimer’s Association about recent ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.